Premium
ImmTAV, a New Immunotherapy Targeting the Source of HBV Infection
Author(s) -
Bertoletti Antonio
Publication year - 2020
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.31527
Subject(s) - library science , citation , medical school , medicine , computer science , medical education
Several therapeutic options have been developed to improve our ability to cure chronic HBV infection(1). In this issue of Hepatology, Fergusson et al describe the development of HBV-specific "Immune mobilizing monoclonal T cell receptors Against Virus" (ImmTAV), a novel and elegant immune therapeutic strategy designed to substitute and potentially restore HBV-specific CD8T cells in chronic Hepatitis B (CHB) patients.